New Gradipore CEO makes his mark with restructure
Thursday, 04 July, 2002
The new US-based CEO of bioseparations specialist Gradipore has wasted no time in making his mark on the company, announcing changes to its management structure during a visit to Australia.
Robert Lieb, who was formerly the chair of the company's US subsidiary Gradipore Inc, said his first priority on taking up the CEO role was to restructure the organisation to better address its customers.
"The changes reflect our commitment to doing fewer things and doing them better, and increasing the emphasis on commercialising the company's considerable intellectual property and building shareholder value," Lieb said.
The changes are:
- Tim Wawn (previously CEO and managing director) is now chief operating officer and will also head Gradipore's Australian operations.
- Dr Hari Nair (previously CEO of Gradipore Inc) will head the company's US operations and also serve as general manager of its commercial separations business unit, which markets the Gradiflow separation technology.
- John Manusu will remain executive chairman, but has also been appointed strategic adviser to the CEO, with an eye towards tracking down new business opportunities for Gradipore around the world.
In April, the company unveiled its new strategy to become a global, multi-billion dollar organisation.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
